Trevi Therapeutics (TRVI) Shares Outstanding (2018 - 2026)

Trevi Therapeutics has reported Shares Outstanding for 9 years, with the latest figure at $128.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding rose 28.55% year-over-year to $128.4 million; the trailing twelve-month figure through Mar 2026 stood at $128.4 million (up 28.55% YoY), and the FY2025 full-year result was $128.3 million, up 37.08% from the prior year.
• Shares Outstanding for Q1 2026 stood at $128.4 million, roughly flat from $128.3 million in the prior quarter.
• The five-year high for Shares Outstanding was $128.4 million in Q1 2026, with the low at $30.8 million in Q1 2022.
• Average Shares Outstanding over 5 years is $80.1 million, with a median of $69.0 million recorded in 2024.
• Year-over-year, Shares Outstanding jumped 169.74% in 2022 and grew 9.49% in 2023.
• Tracing TRVI's Shares Outstanding over 5 years: stood at $59.9 million in 2022, then advanced by 13.91% to $68.3 million in 2023, then surged by 37.08% to $93.6 million in 2024, then jumped by 37.08% to $128.3 million in 2025, then advanced by 0.08% to $128.4 million in 2026.
• The last three Shares Outstanding figures came in at $128.4 million (Q1 2026), $128.3 million (Q4 2025), and $128.2 million (Q3 2025), per Business Quant data.

Peer Comparison